The approval by the U.S. health regulator for the use of Remdesivir in the treatment of spiralized patients took place on Thursday, even though the World Health Organization (WHO) said last week that the drug had no substantial effect on patients’ hospital stays. on their chances of survival in a global clinical trial.

Authorization from the U.S. Food and Drug Administration (FDA) signals confidence in the results of a study conducted by Gilead in the United States, which showed that the drug reduced patients’ recovery time, wrote Piper Sandler analyst Tyler Van Buren. in a note to customers.

Remdesivir was already available to treat patients with Covid-19 under an FDA emergency authorization in May after a study by the US National Institutes of Health showed that the drug reduced the length of hospital stay by five days. .

The drug, given intravenously, could generate sales of more than $ 1 billion in the second quarter of this year, at the current level of cases, Van Buren said.

Remdesivir, which will be marketed under the Veklury brand, costs $ 3,120 for a five-day treatment series and $ 2,340 for government procurement, such as that of the Department of Veterans Affairs.